Home / Solutions

Improve every phase of drug development

Each solution assembled to meet a need. Each solution working in concert with the others. Certara seamlessly fuses science, world class modeling, technology, regulatory and industry acumen, like no other. That means we understand regulatory expectations and can guide you across the entire drug development process.

Contact usCertara overview

Drug development solutions for every phase

From discovery, preclinical, early and late clinical, regulatory strategy and market access, Certara provides a multitude of solutions that we tailor to your specific needs.

  1. 1 / 7
    Regulatory
    Streamline submissions with confidence
    Achieve standardized, compliant submissions efficiently with expert regulatory support. Simplify workflows, accelerate document creation, and ensure error-free submissions for a seamless, high-quality regulatory process across global markets.
  2. 2 / 7
    Discovery
    Predict the right design faster for small molecules and biologics
    Start strong by mitigating risks and prioritizing the right compounds for development. Streamline your design-make-test-analyze cycle with our solutions for due diligence and competitive landscape assessment, target product profile (TPP) development, cheminformatics and biosimulation to make predictive, data-driven decisions that enhance efficiency and improve your chances of discovering breakthrough therapies.
  3. 3 / 7
    Preclinical
    Move your candidate to IND
    Don’t leave anything to guesswork. Test your therapeutic strategies with the industry’s gold standard for in silico studies. Progress your in vitro and early in vivo studies into humans with the aid of biosimulation and regulatory strategies that build confidence in your therapeutic window assessment, nonclinical plans including CMC, toxicology, DMPK, and clinical pharmacology, biomarker and regulatory strategies, First-in-Human trial design, and IND support.
  4. 4 / 7
    Early Clinical
    Navigate to your trial with decision power
    We empower you to find the optimal path from the deluge of nonclinical, pharmacokinetic, pharmacodynamic, and clinical data to design the best strategy for trial design dosing and real-time modeling for optimization. As your close partner, we streamline the journey from data to decisions, ensuring faster, informed submissions that increase confidence and efficiency in clinical development.
  5. 5 / 7
    Late Clinical
    Better trials by design
    From protocol to statistical programming, collect the right data, from the right populations, the first time around. Achieve data standardization before study design and robust analysis to support confident and compliant regulatory submissions. Justify your dosing decisions with advanced modeling. Inform your choice of outcomes with AI-empowered meta-analysis, validate data for accuracy, and streamline decision-making across all trial phases for optimal results.
  6. 6 / 7
    Market Access & Commercial
    Maximize value with evidence-based market strategies
    Achieve your product’s full potential with effective pricing, reimbursement, and patient access strategies aligned to your target product profile. Leverage real-time, real-world, data-agnostic insights to strengthen your market positioning, secure optimal coverage, and ensure broad accessibility across markets. Engage payers and other stakeholders with interactive, evidence-driven stories. Demonstrate your therapy’s value with confidence and achieve success in reimbursement negotiations.
  7. 7 / 7
    Strategic Leadership
    Optimize drug development with innovative, proven solutions
    The power to transform your pipeline is yours. We invite you to partner with us to pick the best path forward, offering innovative yet proven solutions that de-risk and prioritize your portfolio. With decades of expertise, we provide insights to identify your portfolio’s best bets, helping you make the next best decisions. From early-phase research to regulatory submission and beyond, we streamline, accelerate, and ensure accuracy and compliance at every stage.

Expert support in every phase

We’re with you every step of the way. Subject matter experts are there to guide you from one milestone to the next, leveraging decades of experience and advanced technology to speed your journey with certainty.

60,000
drug developers are end-users worldwide
1550
team of experts

“Certara’s contribution to the drug development program for Nurtec™ ODT was substantial. Their clinical pharmacology representative worked seamlessly with the Biohaven Development Team. Certara’s considerable expertise in clinical pharmacology and pharmacometrics and flawless execution supported Nurtec™’s clinical development team and helped to prepare the clinical pharmacology NDA components.“

Richard Bertz, PhD
Senior Vice President, Clinical Pharmacology & Pharmacometrics at Biohaven Pharmaceuticals

Our solutions at work

View all
1 / 6
Publication

Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions

Early Feasibility Assessment (EFA) can impact early drug discovery decisions such as determining feasibility of drugging a target, prioritizing between targets, or defining optimal drug properties for a target product profile (TPP).
Read more
3 / 6
On-Demand Webinar

Improved Translation of Clinical TCE Dosing with Mechanistic Modeling

Abstract: Speaker: Marc Presler, PhD, Associate Director, QSP Recorded on Thursday, July 20, 2023 This work was initially presented by Applied BioMath. Applied BioMath was acquired by Certara in December...
Watch now
6 / 6
Podcast

How Generative AI is Unlocking Insights to Expand Drug Development with Dr. Chris Bouton

From accelerating therapeutic innovation to breaking down data silos, this episode dives into how AI is unlocking insights to expand drug development.
Listen now

We can solve your challenge. Contact us.

At Certara, our philosophy is to start with you. Contact us today so that we can discuss your specific questions.

Certara’s customers have received 90% or more of all novel drug approvals by the FDA from 2014 through 2025.
Certara addresses challenges at any phase of development
Talk with the right expert at the right time

Send an Inquiry